Dublin, March 07, 2018 -- The "Global Allergy Partnering 2012 to 2018" report has been added to ResearchAndMarkets.com's offering.
The Global Allergy Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.
The report provides understanding and access to the partnering deals and agreements entered into by the world's leading healthcare companies.
The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
This data driven report contains multiple links to online copies of actual deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Key Topics Covered:
Executive Summary
Chapter 1 - Therapy Partnering trends in numbers
Partnering in numbers - by year
Partnering in numbers - most active
Partnering in numbers - by industry sector
Partnering in numbers - by deal type
Partnering in numbers - by technology type
Partnering in numbers - by stage of development
Chapter 2 - Most active dealmakers
Chapter 3 - Partnering deals directory
Partnering deals directory - by company A-Z
Partnering deals directory - by deal value
Partnering deals directory - by industry sector
Partnering deals directory - by deal type
Partnering deals directory - by stage of development
Partnering deals directory - by technology area
Chapter 4 - Partnering deals with a contract document
Chapter 5 - M&A in numbers
M&A in numbers - by year
Chapter 6 - M&A deals directory
M&A deals directory - by company A-Z
M&A deals directory - by deal value
Chapter 7 - Financing in numbers
Financing in numbers - by year
Financing in numbers - by financing type
Chapter 8 - Financing deals directory
Financing deals directory - by company A-Z
Financing deals directory - by deal value
Financing deals directory - by financing type
For more information about this report visit https://www.researchandmarkets.com/research/3q8d4g/global_allergy?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Allergy Drugs


Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Instagram Outage Disrupts Thousands of U.S. Users
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 



